Maternal and Neonatal Complications of Methamphetamine Use during Pregnancy
Table 2
Comparison of pregnancy outcomes between the study and control group.
Study (n = 103)
Control (n = 103)
Crude OR
95%CI
value
GA (weeks)
37.0 ± 2.6
38.1 ± 1.7
—
—
<0.001
Preterm birth rate
34 (33.3)
12 (11.7)
3.73
1.80–7.74
<0.001
Late preterm
26 (25.2)
11 (10.7)
2.82
1.33–6.08
0.253
PIH∗
GHT
15 (14.6)
1 (1.0)
17.43
2.51–134.38
<0.001
PE
5 (4.9)
4 (3.9)
1.26
0.32–4.84
0.749
SPE
7 (6.8)
1 (1.0)
7.43
0.89–61.57
0.065
Vaginal delivery
83 (80.6)
72 (69.9)
1.78
0.93–3.40
0.075
Low APGAR
2 (1.9)
1 (1)
2.01
0.18–22.62
0.560
BW (g)
2779.1 ± 486.6
3049.5 ± 510
—
—
<0.001
<2500
28 (27.2)
11 (10.7)
3.12
1.45–6.68
0.004
2500–4000
73 (70.9)
89 (86.4)
0.38
0.18–0.77
0.011
>4000
2 (1.9)
3 (2)
0.66
0.10–4.03
1
GA: gestational age at delivery, PIH: pregnancy-induced hypertension, GHT: gestational hypertension, PE: preeclampsia with nonsevere feature, SPE: preeclampsia with severe feature, Low APGAR: APGAR score equal to and less than 7 at 5 minutes, BW: average birth weight.
